OFIX News & Events

Consensus $813.57M. Narrows FY25 adjusted EBITDA view to $84M-$86M from $82M-$86M. The company said, "Pro forma net sales expected to range between $810 million to $814 million, excluding sales from the discontinued M6 product lines. This compares to previous net sales guidance of $808 million to $816 million. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. Pro forma non-GAAP adjusted EBITDA is expected to be $84 million to $86 million compared to previous $82 million to $86 million. This range includes the anticipated impact from the discontinuation of the M6 product lines that was previously announced in February 2025. Free cash flow is expected to be positive for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6 product lines."

Reports Q3 revenue $205.63M, consensus $200.01M. "Orthofix delivered another quarter of solid financial performance, marked by accelerating quarterly net sales growth, margin expansion and positive free cash flow that was driven by commercial momentum across our spine and orthopedics businesses," said Massimo Calafiore, President and Chief Executive Officer. "Our U.S. Spine Fixation segment outpaced market growth, fueled by the unique advantages of our 7D FLASH navigation technology. We're especially encouraged by the positive impact of recent distributor transitions, which reinforces the strength of our commercial strategy."